Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs - United Arab Emirates
doi 10.2174/2212697x0301160328201324
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets
Cancer ResearchDrug DiscoveryOncologyPharmacology
2009English

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

Targeting the PI3K/Akt/mTOR Signalling Pathway in Cystic Fibrosis

Scientific Reports
Multidisciplinary
2017English

Targeting the PI3K/AKT/MTOR Pathway in KSHV-associated Cancers

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2009English

Pre-Clinical Activity of Targeting the PI3K/Akt/mTOR Pathway in Burkitt Lymphoma

Oncotarget
Oncology
2018English

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors

Clinical Cancer Research
Cancer ResearchOncology
2019English

PSMA Redirects MAPK to PI3K-AKT Signaling to Promote Prostate Cancer Progression

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2017English

Isorhamnetin Inhibited the Proliferation and Metastasis of Androgen-Independent Prostate Cancer Cells by Targeting the Mitochondrion-Dependent Intrinsic Apoptotic and PI3K/Akt/mTOR Pathway

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy